Prot# CC-5013-DLC-001: A Phase 2/3 Mulitcenter, Randomized Open-Label Stuyd to Compare the Efficacy and Safety of Lenalidomide (Revlimid®) Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma